OneMedNet Corp provides healthcare data and software solutions focused on regulatory-grade, AI-ready real-world data for life sciences, medical device, research, and AI customers. Company news commonly centers on the OneMedNet iRWD™ platform, its Palantir Foundry-powered search and data access capabilities, and the commercialization of subscription-based real-world data products.
Recurring developments include platform launches, bookings and revenue updates, data licensing agreements, and collaborations that expand disease-specific and multimodal datasets. Recent company updates have discussed oncology, autoimmune, neurotechnology, medical imaging, electronic health records, longitudinal patient data, cohort discovery, and real-world evidence generation.
OneMedNet (ONMD) reported approximately $18.76 million in year-to-date contracted bookings as of November 6, 2026, alongside a commercial growth recap. Contracted demand stands at nearly 14 times full-year 2025 bookings. Of the bookings reported, $1.388 million has been converted to revenue through September 30, 2026.
The “OneMedNet by the Numbers” recap draws on the company’s November 6 financial outlook, earlier public disclosures and SEC filings. The bookings and revenue-conversion figures cover different reporting cutoffs.
OneMedNet (ONMD) signed its 13th channel partnership, enabling an AI-powered healthcare intelligence company to resell its multimodal clinical data. The agreement is its third AI-focused channel partnership and adds approximately 25% to its sales funnel.
The unnamed partner will combine OneMedNet’s U.S.-sourced, de-identified clinical data with its own claims, pharmacy and encounter data covering hundreds of millions of U.S. patient journeys. OneMedNet retains direct control of data sourcing, curation and de-identification. Its network encompasses more than 90 million patient journeys and 270 million studies. The company intends the combined offering to support healthcare AI model training, clinical development, evidence generation, market access, and research on health economics and outcomes.
OneMedNet (ONMD) expects approximately $1 million in preliminary third-quarter 2026 revenue and issued a fourth-quarter revenue forecast. For the quarter ended September 30, 2026, expected revenue represents a 242% increase from the quarter ended June 30, 2026, and a 465% increase from the prior-year quarter.
The company forecasts approximately $12 million to $14 million in fourth-quarter 2026 revenue, pending anticipated customer acceptance of delivered data by quarter-end. OneMedNet said it began delivering on its growing sales funnel at scale during the third quarter, with order timing and scaled delivery weighting revenue toward the fourth quarter. Third-quarter figures remain preliminary and subject to finalization and adjustment during preparation of the quarterly report, which the company expects to release by November 16, 2026.
OneMedNet (Nasdaq: ONMD) received a mid six-figure re-order from an existing customer developing artificial intelligence models for radiology.
The order follows delivery of the first dataset under the customer agreement and increases the volume of medical imaging data supplied. It expands an agreement included in the more than $3 million in new bookings announced on June 10, 2026; that figure covers multiple engagements, not this customer alone. The company attributes the repeat order to the quality and completeness of the initial data. Under the agreement, OneMedNet supplies imaging studies with identifying information removed, sourced directly from healthcare provider partners.
OneMedNet (ONMD) received a high six-figure add-on order under its multiyear data licensing agreement with an AI-enabled precision medicine customer. The order exercises an expansion option in the agreement announced September 30, 2026, increasing data volume by 150%. The customer uses the data to train clinical and diagnostic AI models and build a derivative dataset for sale through its own channel.
The structure retains potential recurring sublicensing revenue on future end-customer licenses of that dataset. OneMedNet retains source-data rights, and end customers may not relicense or resell the underlying data.
OneMedNet (ONMD) signed its 12th channel partner agreement, adding a global pharmaceutical intelligence and data provider to its distribution network.
The unnamed partner will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established pharmaceutical customer base worldwide. The agreement extends distribution of real-world data, or information drawn from clinical care. OneMedNet said the partnership expands its pharmaceutical-market reach through established distribution channels.
OneMedNet (ONMD) added a hospital system to its iRWD platform and provider network, with further hospital additions expected under the partnership.
The company expects the network to expand by up to 12 additional hospitals. The partnership adds direct access to medical imaging, clinical reports and associated healthcare data covering patients from diagnosis through treatment and follow-up. OneMedNet expects the expanded network to support AI model development, training and validation, as well as evidence used in regulatory submissions and clinical research. The hospital system was not named.
OneMedNet (ONMD) signed its 11th channel partner agreement with Mediplexus, establishing a distribution channel for its healthcare data in Korea.
Mediplexus, a subsidiary of Korean contract research organization C&R Research, will distribute OneMedNet’s U.S.-sourced Real World Data—data collected from healthcare delivery—alongside its own Korean healthcare data. The agreement extends OneMedNet’s commercial reach into the broader Asia Pacific region. The companies plan to broaden the collaboration in stages after an initial one-year engagement. Mediplexus plans to combine the data with analysis, model validation and regulatory support to help Korean medical device and medical AI companies enter the U.S. market.
OneMedNet (ONMD) signed a seven-figure, multiyear data agreement with an AI-enabled precision medicine company that is its tenth channel partner.
The customer intends to use de-identified clinical data delivered through OneMedNet’s iRWD platform to train clinical and diagnostic AI models and create a licensable dataset combining its molecular data with OneMedNet’s imaging and clinical records over time. OneMedNet earns incremental annual sublicensing revenue on each end-customer license, in addition to the initial data license. The agreement includes an option to expand data volume and contract value. OneMedNet retains source-data rights; end customers may not relicense or resell the underlying OneMedNet data.
OneMedNet (ONMD) will implement a 1-for-10 reverse split of its common shares, effective September 29, 2026.
The split will combine every 10 outstanding shares into one. Outstanding shares will fall from approximately 59,286,450 as of September 24, 2026, to approximately 5,928,645. The authorized share count will not change. Stockholders approved the split on September 18, and the board selected the final ratio. OneMedNet says the split is intended to meet the Nasdaq Capital Market’s minimum bid price requirement for continued listing and broaden investor interest. Split-adjusted trading is expected to begin September 29 under ONMD, with CUSIP number 68270C 202.